title: FDA and Avastin: crossroads in an era of targeted therapies.
authors.affiliation: Women's Cancer Program, USC/Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California Los Angeles, California, USA.
authors.forename: Debu
authors.initials: D
authors.lastname: Tripathy
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality; D017277:Drug Approval; D005260:Female; D006801:Humans; D014481:United States; D014486:United States Food and Drug Administration; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab